Archive · 18 Jul 2026
Rossari Biotech Q1 Profit Rises
Rossari Biotech, a company based in Mumbai, recently shared its financial results for the first three months of 2026.
They made a profit of ₹47.01 crore, which is more than last year but a bit less than the previous quarter.
Their total income was ₹700.39 crore, and they spent ₹653.17 crore.
The company also gave some of its employees the option to buy shares at ₹531 each.
Additionally, they decided to move some of their shares in a foreign company to another of their own companies to make things simpler.
This move is worth about ₹24 crore.
Rossari Biotech reported a net profit of ₹47.01 crore for Q1 2026, up from ₹34.80 crore in the same quarter last year.
Revenue from operations was ₹697.20 crore, a 28.23% increase year-over-year but a slight decrease from the previous quarter.
Total income for the quarter was ₹700.39 crore, with total expenses at ₹653.17 crore.
The company allotted 2,500 equity shares under its Employee Stock Option Plan, increasing the total equity share capital to ₹11.08 crore.
Rossari Biotech approved the transfer of its entire shareholding in Rossari International Limited Company to Rossari (Singapore) Pte. Ltd., valued at approximately ₹24 crore.
- Who
- Rossari Biotech Ltd
- What
- Announced Q1 financial results
- When
- Quarter ended 30 June 2026
- Where
- Mumbai
- Why
- To report financial performance and corporate actions
- Net Profit
- ₹47.01 crore
- Revenue from Operations
- ₹697.20 crore
- Total Income
- ₹700.39 crore
- Total Expenses
- ₹653.17 crore
- Equity Shares Allotted
- 2,500
- Stock Options Granted
- 4,000
- Exercise Price per Option
- ₹531
- Value of Transfer
- ₹24 crore